Branded Generics Market: Global Market Size, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 3,000.00$ 8,900.00

Branded Generics Market By Disease Indication (Cardiovascular Diseases, Diabetes, Cancer, Neurological Disorders, Gastrointestinal Diseases, Dermatology Diseases, and Others), By Route of Administration (Oral, Parenteral, Topical, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, and Online Pharmacies), and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Categories: ,

Report

Description

Branded Generics market size is valued at USD 242.4 billion in 2021 and is expected to grow at a CAGR of 5.9% during the forecast period 2022 to 2028. The global market provides a detailed overview of the Branded Generics market and which can be segmented by disease, route of administration, distribution channel, and region. By disease, the Branded Generics market has been segmented into cardiovascular diseases, diabetes, cancer, neurological disorders, gastrointestinal diseases, dermatology diseases, and others. By disease, the cardiovascular disease segment accounts for increasing sales of branded generics in the global market. According to World Health Organization (WHO), around 17.9 million people die every year from cardiovascular diseases (CVDs) across the world. Correspondingly, 1.13 billion people worldwide have hypertension. This leads to the adoption of branded generics such as anti-hypertensive drugs, which ultimately expands branded generics market.  By route of administration, the Branded Generics market has been segmented into oral, parenteral, topical, and others. By route of administration, the oral segment leads the branded generics market with a significant share. The segment’s growth can be attributed to the convenience factor associated with oral administration. Oral medications are easy to administer and patient compliance with oral medication is more than other routes of administration. Furthermore, tablets and capsules are being made more palatable using sweeteners and colored coatings. Based on the distribution channel, the segment has been segregated into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies. Online Pharmacies are expected to have a considerable growth rate owing to the emergence of e-commerce, and manufacturers are forging alliances with online and retail pharmacies. An unprecedented pandemic of COVID-19 regularised branded generics shopping via online pharmacies. Patients find it easy and timesaving to get their medication from online pharmacies directly. As a result, online pharmacies are projected to gain traction through 2022 and beyond. By region, the North America market is expected to witness the highest market share during the forecast period owing to the well-established healthcare facilities and increasing prevalence of chronic diseases across the region, such as cardiovascular diseases, diabetes, Alzheimer’s diseases, and Parkinson’s diseases boosting the demand of branded generics market.

Key Development:

In May 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the launch of THIOLA (tiopronin) tablets for the presentation of cystine (kidney) stones.

In July 2021, Lupin announced that it will acquire Australia-based Southern Cross Pharma Pvt Ltd (SCP).

Branded Generics Market

MARKET SUMMARY
-
5.9% CAGR
  • Study Period– 2022 – 2028
  • Base Year– 2021
  • CAGR– 5.9%
  • Largest Market– Europe
  • Fastest Growing Market– Asia-Pacific

Branded Generics Market

  • The report on global branded generics market gives historical, current and future market sizes (US$ Bn) based on by disease indication, by route of administration, by distribution channel and geographical regions.
  • branded generics market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Abbott Laboratories (U.S.)
  • Apotex Inc. (Canada)
  • AstraZeneca (U.K)
  • GlaxoSmithKline plc (U.K)
  • Mylan N.V. (U.S.)
  • Pfizer Inc. (U.S)
Branded Generics Market Drivers

Global market is primarily driven by a significant increase in cardiometabolic risk factors among a large proportion of people. The increasing prevalence of cancer cases is also playing an important role in the growth of the Branded Generics Market. However, a major factor, which is anticipated to hamper the growth of the market during the forecast period, is the misapplication of risk evaluation and mitigation strategies (REMS) to branded generics market entry.


Asia Pacific Got Significant Share

Branded Generics Market

Asia-pacific expected to lead the global Branded Generics Market in terms of revenue in over forecast period owing to higher out-of-pocket healthcare expenditure and lack of universal health coverage. Moreover, countries like India, China, and ASEAN countries presented better growth opportunities for the existing and new players in the market. Regions such as Asia Latin America and Eastern Europe projected to grow at significant CAGR over the forecast period

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
Branded Generics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The increasing prevalence of cancer cases is playing a major role in the growth of the branded generics market. Also, many pharmaceutical products become off-patent throughout the forecast period, and the worldwide branded generics market is expected to increase rapidly. Simple marketing approval procedures, new player participation, changing medication procedures, and higher profit margins are all anticipated to boost the global branded generics industry

The introduction of new branded generics, encouraging the usage of branded generics by healthcare suppliers and professionals, and a two-tiered strategy are major key trends pushing the market.

The U.S., China, India, Russia, and Brazil are the key manufacturers of branded generics.

The cardiovascular segment is expected to account for the largest share of the branded generics market during the forecast period, due to the increasing prevalence of the diseases among a large mass.


Report

Table Of Content

1. Research Methodology

      1.1. Secondary and Primary research
            1.1.1. Secondary Sources
            1.1.2. Primary Sources
      1.2. Market Revenue Estimation Methodology
      1.3. Key Assumptions

      1.4. Acronyms

2. Scope of Study

      2.1. Market Definition
      .2. Objective of the Research

      2.3. Regions covered in the study

3. Executive summary

4. Branded Generics in Emerging Countries Market Dynamics

      4.1. Drivers
            4.1.1. Economic Drivers
            4.1.2. Demand Side Drivers
            4.1.3. Supply Side Drivers
      4.2. Restraints
      4.3. Opportunities/Unmet Needs of the Market

      4.4. Trends

5. Unique Features of the Report

      5.1. Competition analysis
      5.2. Regulatory landscape
      5.3. PESTLE analysis

      5.4. Porter’s analysis

6. Branded Generics in Emerging Countries Market Analysis, By Diseases Indication, 2013 – 2017 and Forecast, 2018 – 2024

      6.1. Cardiovascular Diseases
            6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
            6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      6.2. Diabetes
            6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
            6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      6.3. Cancer
            6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
            6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      6.4. Neurological Disorders
            6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
            6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      6.5. Gastrointestinal Diseases
            6.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
            6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      6.6. Dermatology Diseases
            6.6.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
            6.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      6.7. Others
            6.7.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

            6.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7. Branded Generics in Emerging Countries Market Analysis, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024

      7.1. Oral
            7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)
            7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      7.2. Parenteral
            7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)
            7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      7.3. Topical
            7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)
            7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      7.4. Others
            7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)

            7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8. Branded Generics in Emerging Countries Market Forecast, By Distribution Channel, 2013 – 2017 and Forecast, 2018 – 2024

      8.1. Hospital Pharmacies
            8.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)
            8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      8.2. Retail Pharmacies
            8.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)
            8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      8.3. Drug Stores
            8.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)
            8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
      8.4. Online Pharmacies
            8.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024(Revenue, USD Mn)

            8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

9. Branded Generics in Emerging Countries Market Analysis, By Region, 2013 – 2017 and Forecast, 2018 – 2024

      9.1. Europe Branded Generics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
            9.1.1. Diseases Indication Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.1.1.1. Cardiovascular Diseases
                  9.1.1.2. Diabetes
                  9.1.1.3. Cancer
                  9.1.1.4. Neurological Disorders
                  9.1.1.5. Gastrointestinal Diseases
                  9.1.1.6. Dermatology Diseases
                  9.1.1.7. Others
            9.1.2. Route of Administration Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.1.2.1. Oral
                  9.1.2.2. Parenteral
                  9.1.2.3. Topical
                  9.1.2.4. Others
            9.1.3. Distribution Channel Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.1.3.1. Hospital Pharmacies
                  9.1.3.2. Retail Pharmacies
                  9.1.3.3. Drug Stores
                  9.1.3.4. Online Pharmacies
            9.1.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.1.4.1. Russia
                  9.1.4.2. Romania
                  9.1.4.3. Rest of Europe
      9.2. Asia-Pacific Branded Generics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
            9.2.1. Diseases Indication Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.2.1.1. Cardiovascular Diseases
                  9.2.1.2. Diabetes
                  9.2.1.3. Cancer
                  9.2.1.4. Neurological Disorders
                  9.2.1.5. Gastrointestinal Diseases
                  9.2.1.6. Dermatology Diseases
                  9.2.1.7. Others
            9.2.2. Route of Administration Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.2.2.1. Oral
                  9.2.2.2. Parenteral
                  9.2.2.3. Topical
                  9.2.2.4. Others
            9.2.3. Distribution Channel Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.2.3.1. Hospital Pharmacies
                  9.2.3.2. Retail Pharmacies
                  9.2.3.3. Drug Stores
                  9.2.3.4. Online Pharmacies
            9.2.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.2.4.1. China
                  9.2.4.2. India
                  9.2.4.3. ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
                  9.2.4.4. Rest of Asia- Pacific
      9.3. Latin America Branded Generics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
            9.3.1. Diseases Indication Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.3.1.1. Cardiovascular Diseases
                  9.3.1.2. Diabetes
                  9.3.1.3. Cancer
                  9.3.1.4. Neurological Disorders
                  9.3.1.5. Gastrointestinal Diseases
                  9.3.1.6. Dermatology Diseases
<

            /div>

      9.3.1.7. Others
            9.3.2. Route of Administration Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.3.2.1. Oral
                  9.3.2.2. Parenteral
                  9.3.2.3. Topical
                  9.3.2.4. Others
            9.3.3. Distribution Channel Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.3.3.1. Hospital Pharmacies
                  9.3.3.2. Retail Pharmacies
                  9.3.3.3. Drug Stores
                  9.3.3.4. Online Pharmacies
            9.3.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.3.4.1. Brazil
                  9.3.4.2. Poland
                  9.3.4.3. Argentina
                  9.3.4.4. Mexico
                  9.3.4.5. Venezuela
                  9.3.4.6. Rest of Latin America
      9.4. Rest of the World (RoW) Branded Generics Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
            9.4.1. Diseases Indication Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.4.1.1. Cardiovascular Diseases
                  9.4.1.2. Diabetes
                  9.4.1.3. Cancer
                  9.4.1.4. Neurological Disorders
                  9.4.1.5. Gastrointestinal Diseases
                  9.4.1.6. Dermatology Diseases
                  9.4.1.7. Others
            9.4.2. Route of Administration Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.4.2.1. Oral
                  9.4.2.2. Parenteral
                  9.4.2.3. Topical
                  9.4.2.4. Others
            9.4.3. Distribution Channel Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.4.3.1. Hospital Pharmacies
                  9.4.3.2. Retail Pharmacies
                  9.4.3.3. Drug Stores
                  9.4.3.4. Online Pharmacies
            9.4.4. Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) and Y-o-Y Growth (%)
                  9.4.4.1. Turkey
                  9.4.4.2. Saudi Arabia
                  9.4.4.3. South Africa

                  9.4.4.4. Egypt

10. Competition Landscape

      10.1. Strategic Dashboard of Top Market Players
      10.2. Company Profiles (Introduction, Financial Analysis, Products & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
            10.2.1. Abbott Laboratories (U.S.)
            10.2.2. Apotex Inc. (Canada)
            10.2.3. AstraZeneca (U.K)
            10.2.4. CSPC Pharmaceutical Group Limited. (China)
            10.2.5. Dr. Reddy’s Laboratories Ltd. (India)
            10.2.6. GlaxoSmithKline plc (U.K)
            10.2.7. Mylan N.V. (U.S.)
            10.2.8. Nichi-Iko Pharmaceutical Co., Ltd ( Japan)
            10.2.9. Novartis AG (Switzerland)
            10.2.10. Pfizer Inc. (U.S)
            10.2.11. Sanofi (France)
            10.2.12. Sun Pharmaceutical Industries Ltd. (India)
            10.2.13. Teva Pharmaceutical Industries Ltd (Israel)

            10.2.14. Valeant Pharmaceuticals International, Inc. (Canada)


Report

Company Profile

  • Abbott Laboratories (U.S.)
  • Apotex Inc. (Canada)
  • AstraZeneca (U.K)
  • Reddy’s Laboratories Ltd. (India)
  • GlaxoSmithKline plc (U.K)
  • Mylan N.V. (U.S.)
  • Pfizer Inc. (U.S)
  • Novartis AG (Switzerland)
  • Sanofi (France)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • Valeant Pharmaceuticals International, Inc. (Canada)

Description

Branded Generics market size is valued at USD 242.4 billion in 2021 and is expected to grow at a CAGR of 5.9% during the forecast period 2022 to 2028. The global market provides a detailed overview of the Branded Generics market and which can be segmented by disease, route of administration, distribution channel, and region. By disease, the Branded Generics market has been segmented into cardiovascular diseases, diabetes, cancer, neurological disorders, gastrointestinal diseases, dermatology diseases, and others. By disease, the cardiovascular disease segment accounts for increasing sales of branded generics in the global market. According to World Health Organization (WHO), around 17.9 million people die every year from cardiovascular diseases (CVDs) across the world. Correspondingly, 1.13 billion people worldwide have hypertension. This leads to the adoption of branded generics such as anti-hypertensive drugs, which ultimately expands branded generics market.  By route of administration, the Branded Generics market has been segmented into oral, parenteral, topical, and others. By route of administration, the oral segment leads the branded generics market with a significant share. The segment’s growth can be attributed to the convenience factor associated with oral administration. Oral medications are easy to administer and patient compliance with oral medication is more than other routes of administration. Furthermore, tablets and capsules are being made more palatable using sweeteners and colored coatings. Based on the distribution channel, the segment has been segregated into hospital pharmacies, retail pharmacies, drug stores, and online pharmacies. Online Pharmacies are expected to have a considerable growth rate owing to the emergence of e-commerce, and manufacturers are forging alliances with online and retail pharmacies. An unprecedented pandemic of COVID-19 regularised branded generics shopping via online pharmacies. Patients find it easy and timesaving to get their medication from online pharmacies directly. As a result, online pharmacies are projected to gain traction through 2022 and beyond. By region, the North America market is expected to witness the highest market share during the forecast period owing to the well-established healthcare facilities and increasing prevalence of chronic diseases across the region, such as cardiovascular diseases, diabetes, Alzheimer’s diseases, and Parkinson’s diseases boosting the demand of branded generics market.

Key Development:

In May 2021, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the launch of THIOLA (tiopronin) tablets for the presentation of cystine (kidney) stones.

In July 2021, Lupin announced that it will acquire Australia-based Southern Cross Pharma Pvt Ltd (SCP).

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX